AstraZeneca’s Farxiga (dapagliflozin) Fails to Meet its Primary Endpoint in P-III DARE-19 Trial for COVID 19

 AstraZeneca’s Farxiga (dapagliflozin) Fails to Meet its Primary Endpoint in P-III DARE-19 Trial for COVID 19

Shots:

  • The P-III DARE-19 trial involves assessing the efficacy and safety of Farxiga vs PBO in addition to SoC therapy in 1,250 hospitalized patients with COVID-19 who are at high risk of developing serious complications
  • The trial fails to meet its 1EP of prevention measures organ dysfunction, all-cause mortality, and recovery measuring a change in clinical status (from early recovery to death) @30days, safety and tolerability profile of Farxiga was consistent with the established safety profile of the therapy
  • Farxiga (PO, qd) is an SGLT2 inhibitor, approved for HFrEF in adults with/out T2D. The results will be presented at ACC in May’2021

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: The Scientist Magazine

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post